Betta Pharmaceuticals Co., Ltd.

Betta Pharmaceuticals Co., Ltd. saw a notable stock decline today, underperforming compared to the broader market. The company has faced significant challenges over the past year and five years, with declining profits and elevated valuation metrics, despite offering a modest dividend yield. Its market capitalization is CNY 18,971 million.

Betta Pharmaceuticals Co., Ltd. saw a significant daily increase, contrasting with the modest rise of the China Shanghai Composite. However, the company has struggled over the past year, with a notable decline in net profit and mixed financial metrics, indicating potential concerns about its long-term performance.

Betta Pharmaceuticals Co., Ltd. faced a significant decline in stock performance on March 3, 2026, with ongoing challenges reflected in its recent metrics. The company has experienced notable drops over various time frames, while its long-term growth indicators suggest a disconnect with current investor expectations amid a premium valuation.

Betta Pharmaceuticals Co., Ltd. faced notable market activity on October 15, 2025, with a significant decline in stock value. Despite recent short-term challenges, the company has shown strong annual performance, outperforming the China Shanghai Composite. Financial metrics reveal a market capitalization of CNY 27,699 million and a price-to-earnings ratio of 72.00.

Betta Pharmaceuticals Co., Ltd. faced a challenging trading day on October 14, 2025, with a notable stock decline. Despite recent downturns, the company has achieved a strong annual return and maintains a significant market capitalization, alongside a high price-to-earnings ratio and a modest dividend yield.

Betta Pharmaceuticals Co., Ltd. saw a significant decline in its stock today, contrasting with the broader market's performance. Despite recent losses, the company has demonstrated strong long-term growth, with notable increases in stock value over the past year and three years, alongside key financial metrics reflecting its industry standing.

Betta Pharmaceuticals Co., Ltd. saw a decline in its stock today, contrasting with a gain in the China Shanghai Composite. Despite recent fluctuations, the company has achieved significant annual growth and maintains a strong market capitalization, price-to-earnings ratio, and return on equity, reflecting its long-term resilience.